RxDoctor Payments Data

Wenjay Sung

Foot & Ankle Surgery · Arcadia, CANPI 1649433129

Payments from drug & device makers

$27,617in general payments, 2019–2025

Across 255 payments — averaging $108.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acera Surgical, Inc.$11K
  • In2bones USA, LLC$5K
  • Linvatec Corporation$2K
  • Smith+Nephew$1K
  • Zimmer Biomet$993
  • Amgen$909
  • plus $5K from 39 others
$7,080in research payments, 2019–2025

Across 2 payments — averaging $3540.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acera Surgical, Inc.$7K

What the payments were for

  • Consulting fees$6,70024%
  • Travel & lodging$9553%
  • Food & beverage$9,28934%
  • Other$10,67339%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,617 in reported general payments places this provider in the 90th percentile of 1,126 foot & ankle surgery providers in California.

See all foot & ankle surgery providers in California

Medicare billing

Part B allowed, 2024
$307,996
Medicare patients
410
Services billed
1,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.33$13,644
Ketoconazole76$673
Econazole Nitrate19$291
Terbinafine Hcl23$277
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$200
Gabapentin29$175
Cephalexin32$151
Ibuprofen25$100
SsdSilver Sulfadiazine15$98
Silver Sulfadiazine20$81
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$53
Meloxicam11$20

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,248$13,64433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,126 foot & ankle surgery providers in California.

Other foot & ankle surgery in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →